Abstract
Despite recent advances in the diagnoses and treatment of breast cancer, this disease continues to be a major cause of death. One of the biggest challenges in breast cancer treatment is bone metastasis. Breast cancer cells (BCCs) are capable of migrating to the bone marrow and utilizing the marrow microenvironment to remain quiescent. While exhibiting quiescence in the marrow, BCCs can evade the effects of conventional cancer treatments such as chemotherapy. Therefore, scientists must find a new paradigm to target these quiescent BCCs. The development of potential targets may require a more comprehensive understanding of the marrow microenvironment and its regulators. The preprotachykinin-1 (PPT-I) gene encodes for the tachykinin peptides, which interact with neurokinin (NK) receptors. Studies have correlated this interaction with BCC integration into the bone marrow and breast cancer progression. In this review, we discuss the roles that different factors of the marrow microenvironment play in breast cancer and targets of NK receptors as potential treatment options.
Keywords: Neurokinin receptor, breast cancer, tachykinins, CXCR4, SDF-1α, bone marrow, substance P, preprotachykinin-I
Current Drug Discovery Technologies
Title: Neurokinin Receptors as Potential Targets in Breast Cancer Treatment
Volume: 5 Issue: 1
Author(s): Pranela Rameshwar, Bobby Y. Reddy, Katarzyna A. Trzaska, Raghav G. Murthy and Peter Navarro
Affiliation:
Keywords: Neurokinin receptor, breast cancer, tachykinins, CXCR4, SDF-1α, bone marrow, substance P, preprotachykinin-I
Abstract: Despite recent advances in the diagnoses and treatment of breast cancer, this disease continues to be a major cause of death. One of the biggest challenges in breast cancer treatment is bone metastasis. Breast cancer cells (BCCs) are capable of migrating to the bone marrow and utilizing the marrow microenvironment to remain quiescent. While exhibiting quiescence in the marrow, BCCs can evade the effects of conventional cancer treatments such as chemotherapy. Therefore, scientists must find a new paradigm to target these quiescent BCCs. The development of potential targets may require a more comprehensive understanding of the marrow microenvironment and its regulators. The preprotachykinin-1 (PPT-I) gene encodes for the tachykinin peptides, which interact with neurokinin (NK) receptors. Studies have correlated this interaction with BCC integration into the bone marrow and breast cancer progression. In this review, we discuss the roles that different factors of the marrow microenvironment play in breast cancer and targets of NK receptors as potential treatment options.
Export Options
About this article
Cite this article as:
Rameshwar Pranela, Reddy Y. Bobby, Trzaska A. Katarzyna, Murthy G. Raghav and Navarro Peter, Neurokinin Receptors as Potential Targets in Breast Cancer Treatment, Current Drug Discovery Technologies 2008; 5(1) . https://dx.doi.org/10.2174/157016308783769450
DOI https://dx.doi.org/10.2174/157016308783769450 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets The First Organometallic Selective Estrogen Receptor Modulators (SERMs) and Their Relevance to Breast Cancer
Current Medicinal Chemistry Natural Substances in the Treatment of Cystic Fibrosis
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Comparison of Paraben Stability in Human and Rat Skin
Drug Metabolism Letters Acyl Thiourea Derivatives Containing Pyrazole Ring Selective Targeting of Human Aurora Kinases in Breast and Bone Cancer
Letters in Drug Design & Discovery Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
CNS & Neurological Disorders - Drug Targets Sleep and COPD
Current Respiratory Medicine Reviews Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2)
Current Cancer Drug Targets Breast Cancer Risks in Premenopausal Women: A Review
Current Women`s Health Reviews Nuclear Magnetic Resonance Spectroscopy and Genetic Disorders
Current Medicinal Chemistry Review: Metabolism of Immunosuppressant Drugs
Current Drug Metabolism Editorial [Hot Topic: Stem Cells and Tissue Regeneration (Executive Guest Editor: Roberta Di Pietro)]
Current Pharmaceutical Design Immune-Neuroendocrine Interactions Involving Thymus and Pineal Gland in Stem Cell Therapy of Age-Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Evidence for the Involvement of Resistin in Inflammation and Cardiovascular Disease
Current Diabetes Reviews <i>Circular RNA NF1-419</i> Inhibits Proliferation and Induces Apoptosis by Regulating Lipid Metabolism in Astroglioma Cells
Recent Patents on Anti-Cancer Drug Discovery Cardiotoxicity of Tyrosine-Kinase-Targeting Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry New Approaches to Photodynamic Therapy from Types I, II and III to Type IV Using One or More Photons
Anti-Cancer Agents in Medicinal Chemistry Combined <i>Curcuma longa</i> and <i>Cratoxylum formosum</i> Extracts Possess Anti-liver Cancer and Anti-HBV Activities in HepG2.2.15
Current Traditional Medicine Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Molecular Dynamics Simulations of Intrinsically Disordered Proteins in Human Diseases
Current Computer-Aided Drug Design